Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US09073M1045
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000C15114
TECH
Bio-Techne Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Bio-Techne Corp
ISIN
US09073M1045
TICKER
TECH
MIC
XNAS
REUTERS
TECH.OQ
BLOOMBERG
TECH US
So., 23.08.2026       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 24.08.2026 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its ex-dividend/interest day on 24.08.2026...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Sa., 22.08.2026       Bio-Techne
US09073M1045

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sade...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 21.08.2026 und ex Dividende/Zinsen am 24.08.2026 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its pre-dividend/interest day on 21.08.2026 and its ex-dividend/interest day on 24.08.2026...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 13.08.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividen...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.Fourth Quarter FY2026 HighlightsFourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion.GAAP E...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026. Future cash dividends will be c...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 08.07.2026       Bio-Techne
US09073M1045

Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture WorkflowsNew heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolioAI-guided protein design supports improved consistency, performance and scalability in com...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 29.06.2026       Bio-Techne
US09073M1045

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that the...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Fr., 26.06.2026       Bio-Techne
US09073M1045

NEW YORK, June 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Bio-Techne
US09073M1045

MILWAUKEE, June 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn ho...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 25.06.2026       Bio-Techne
US09073M1045

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sade...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Bio-Techne
US09073M1045

Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering,...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Bio-Techne
US09073M1045

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTIL BIO-TECHNE CORP. DL-,01 EUR US09073M1045 25.06.2026 11:42 CET START RESTART AUCTION: 11:42 EARLIEST START OF PRICE DETERMINATION: 11:47...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Bio-Techne
US09073M1045

Instrument ID [7997] (TE1 - US09073M1045) suspended...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Bio-Techne
US09073M1045

Instrument ID [16257120] (TE1 - US09073M1045) suspended...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       Bio-Techne
US09073M1045

New integrated workflow combines icIEF fractionation and mass photometryEnables direct characterization of aggregation and size within icIEF-resolved charge variantsFour-hour workflow reduces development risk and accelerates biosimilar manufacturingMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH),...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 03.06.2026       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY hat seinen ersten Handelstag am 04.06.2026: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its first trading date on 04.06.2026: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Sa., 16.05.2026       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 18.05.2026 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its ex-dividend/interest day on 18.05.2026...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 14.05.2026       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 15.05.2026 und ex Dividende/Zinsen am 18.05.2026 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its pre-dividend/interest day on 15.05.2026 and its ex-dividend/interest day on 18.05.2026...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGA...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 06.05.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be consider...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 04.05.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Bio-Techne
US09073M1045

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brand...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Bio-Techne
US09073M1045

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brand...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Bio-Techne
US09073M1045

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brand...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Bio-Techne
US09073M1045

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brand...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Bio-Techne
US09073M1045

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brand...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time:8:00 a.m. CDTDate:May 6, 2026Dial-in...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Bio-Techne
US09073M1045

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets. Enhancements strengthen the fully integ...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 16.02.2026       Bio-Techne
US09073M1045

Ella benchtop instrument is now CE-IVD marked and available for sale in the EUEnables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on timeProvides confidence for use in clinical trials and in-house test development   MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Tec...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       Bio-Techne
US09073M1045

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Te...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 04.02.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends wi...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Bio-Techne
US09073M1045

Fully defined, synthetic ECM designed to improve reproducibility and reduce lot-to-lot variabilitySupports standardization of scalable 3D stem cell and organoid workflowsSynthetic alternative to traditional matrices, enabling consistent performance while aligning with regulatory and translational initiativesMINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 28.01.2026       Bio-Techne
US09073M1045

Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insightsSupports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validated biomarkersAutomated immunoassay workflow reduces variability; total runtime is under three hoursMINNEAPOLIS, Jan. 28, 2026 /PRNewswire/ -- Bio-Tech...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Bio-Techne
US09073M1045

MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time: 8:00 a.m. CSTDate: February 4,...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 23.12.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Tec...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Bio-Techne
US09073M1045

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexingEnables up to 24 targets per sample and supports complex assay configurationsStrengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 complianceMINNEAPOLIS, De...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:8th Annual Evercore Healthcare Conference 2025December 2, 20258:20 AM ESTCiti's 2025 Global Healthcare ConferenceDecember 3, 20253:15 PM EST53rd Annual Nasdaq Investor ConferenceDecember 9, 202...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Stifel 2025 Healthcare Conference November 11, 2025 9:20...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on Novembe...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Bio-Techne
US09073M1045

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.  Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Bio-Techne
US09073M1045

Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue section Automates spatial multiomic workflows with the BOND RX platform from Leica...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Bio-Techne
US09073M1045

Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products. The partnership will leverage Bio-Techne’s extensive international sales and marketing channels to pr...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results. Access to the discussion may be obtai...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Fr., 26.09.2025       Bio-Techne
US09073M1045

RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue sectionTechnologies support spatial multiomic analysis and deeper insights for pathology workflowsResearch highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonalityMINNEAPOLIS, Sept. 26, 2025...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 24.09.2025       Bio-Techne
US09073M1045

Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the compa...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 09.09.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., Sept. 9, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturin...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
So., 17.08.2025       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 18.08.2025 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its ex-dividend/interest day on 18.08.2025...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 14.08.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical C...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: Augus...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink